Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Polaryx Therapeutics, Inc

PLYX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.99

▲ +6.42%

Market Cap $99.19M · Vol 9.93K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$99.19M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

42.51

Momentum

Beta

N/A

vs Market

52W High

$48.91

95.93% below

52W Low

$1.86

7.28% above

Volume

9.93K

Avg 20.42K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

30.08%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Polaryx Therapeutics, Inc (PLYX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PLYX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.78%

-2.93%

-44.72%

-28.16%

YTD

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-30,356,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-829.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	49.85M

Technical Indicators

50-Day SMA	$2.29
200-Day SMA	$N/A
RSI (14)	42.51
Beta	N/A
52-Week High	$48.91
52-Week Low	$1.86

Volume Today	9.93K
Avg Daily Volume (30D)	20.42K
Relative Volume	0.49x
Volatility (10D)	137.74
Volatility (30D)	96.30
Free Float	30.08%

Analyst Consensus

BUY

Current Price $1.99

Mean Target $7.50

52W Low$1.86 52W High$48.91

Current

Target

$1.86 $48.91

Current Analyst target

+276.88% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01ZPFWWC1

ISINUS73110F1003

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.